Vitae Pharmaceuticals has filed for an IPO and set its estimated price range at $11 to $13 per share. Pricing at the midpoint, the company could raise $60 million in the offering and garner a market cap of near $186 million. The clinical-stage biopharma, which plans to list on the NASDAQ under the symbol VTAE, focuses on discovering and developing novel, small-molecule drugs for diseases with significant unmet medical need. Its product VTP-43742, a treatment for psoriasis, is expected to advance into Phase 1 clinical trials in the first half of 2015. Shareholders in the company include Prospect Venture Partners (23.3% pre-IPO stake), New Enterprise Associates (17.8%), Venrock (15.6%) and Atlas Venture (11.2%), among others.